When did Kura Oncology report Q1 2025 earnings?

Kura Oncology (KURA) reported Q1 2025 earnings on May 1, 2025 after market close.

What were Kura Oncology's Q1 2025 revenue and EPS?

Kura Oncology reported revenue of $14.1M and diluted EPS of $-0.66 for Q1 2025.

Did Kura Oncology beat estimates in Q1 2025?

Revenue missed the consensus estimate of $66.7M by $52.6M. EPS missed the consensus estimate of $-0.51 by $0.15.

How did Kura Oncology's Q1 2025 results compare year-over-year?

Compared to the same quarter a year prior, diluted EPS declined 11.9% from $-0.59.

Where can I find Kura Oncology's Q1 2025 SEC filings?

You can read the 10-Q periodic report (0000950170-25-061848) directly on SEC EDGAR. The filing index links above go to sec.gov.

Kura Oncology KURA Q1 2025 earnings

Reported May 1, 2025 · After market close

Revenue$14.1MMiss by $52.6M Diluted EPS-$0.66Miss by $0.15

Revenue estimate$66.7M

EPS estimate-$0.51

Next report

Aug 6, 2026 (In 3 weeks)

Revenue estimate$20.2M

EPS estimate-$0.89

Financials

Q1 2025

Income statement

See full

Revenue$14.1M+4.7%

Operating income-$64.7M-18.8%

Net income-$57.4M-16.0%

EPS (diluted)-$0.66-11.9%

Balance sheet

See full

Cash & equivalents$51.3M+23.5%

Total debt$19.4M+14.0%

Total equity$364.4M-27.9%

Total assets$743.8M+34.3%

Cash flow

See full

Operating cash flow-$71.9M-47.3%

CapEx$292.0K+248%

Free cash flow-$72.2M-47.6%

Valuation & ratios

Valuation

as of 03/31/25

See full

Market cap$532.98M-70.2%

Enterprise value$501.07M-71.6%

P/S9.8×-123×

Profitability

See full

Operating margin-373.2%-156pp

Net margin-333.6%-141pp

FCF margin202.8%+111pp

Returns & leverage

See full

Return on equity-41.8%+5.7pp

Debt / equity0.1×0.0×

Current ratio8.1×-8.6×

Segments

By product

See full

License And Collaboration Revenue$14.1M+4.7%

Versus estimates

Revenue

Q1 2026$18.3MMiss by $7.7M Q4 2025$17.3MMiss by $18.1M Q3 2025$20.8MMiss by $30.7M Q2 2025$15.3MMiss by $49.7M

Q1 2025$14.1MMiss by $52.6M

Q4 2024$53.9MMiss by $4.1M

Diluted EPS

Q1 2026-$0.83Beat by $0.05 Q4 2025-$0.92Miss by $0.20 Q3 2025-$0.85Miss by $0.28 Q2 2025-$0.75Miss by $0.90

Q1 2025-$0.66Miss by $0.15

Q4 2024-$0.22Beat by $0.43

Ask the moment Kura Oncology reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Kura Oncology report Q1 2025 earnings?: Kura Oncology (KURA) reported Q1 2025 earnings on May 1, 2025 after market close.
What were Kura Oncology's Q1 2025 revenue and EPS?: Kura Oncology reported revenue of $14.1M and diluted EPS of $-0.66 for Q1 2025.
Did Kura Oncology beat estimates in Q1 2025?: Revenue missed the consensus estimate of $66.7M by $52.6M. EPS missed the consensus estimate of $-0.51 by $0.15.
How did Kura Oncology's Q1 2025 results compare year-over-year?: Compared to the same quarter a year prior, diluted EPS declined 11.9% from $-0.59.
Where can I find Kura Oncology's Q1 2025 SEC filings?: You can read the 10-Q periodic report (0000950170-25-061848) directly on SEC EDGAR. The filing index links above go to sec.gov.